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Downward Vertical Gaze Palsy As A Prominent Manifestation Of Episodic Ataxia 
Type 2: A Case Report
Abstract
Objective
Episodic ataxia type 2 (EA2) is an inherited autosomal dominant disorder 
characterized by intermittent ataxia, nausea, vomiting, dysarthria, or nystagmus. 
We report a case of EA2, which downward gaze palsy exists as a common sign 
in all her attacks. Responsiveness of EA2 to acetazolamide was observed in this 
patient.
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CASE REPORT
Introduction
Intermittent and recurrent ataxias are described in several vestibular, metabolic, 
vascular, and genetic disorders (1). Episodic ataxias (EAs) are characterized by 
recurrent episodes of cerebellar ataxia, vertigo, dysarthria, and nystagmus, starting 
in childhood and lasting for minutes or hours, with otherwise normal brain functions 
(2). Data is not available on the exact incidence of EAs, but it seems to occur in 3 to 5 
people per 100,000 in the population (3). Nowadays there are seven recognized EA 
syndromes (numbered 1 to 7). These disorders share some common features: all are 
channelopathies with autosomal-dominant inheritance pattern and are responsive to 
acetazolamide (2). EA1 and EA2 are clinically well described, while the others are 
exceptionally rare (3). Both EA1 and EA2 are the result of ion channel mutations. 
Mutations in a potassium channel gene (KCNA1) located on chromosome 12p13 
underlie EA1, and in a voltage-dependent calcium channel gene (CACNA1A) 
located on chromosome 19p13 can lead to EA2 (4). EA1 is characterized by brief 
episodes of ataxia lasting seconds to minutes, with onset in early childhood and 
often induced by startle or exercise, emotional stress, sudden change in posture, and 
by the continuous interictal myokymia (5,6). EA2, spinocerebellar ataxia type 6 
(SCA6), and familial hemiplegic migraine all represent allelic mutations in the same 
calcium channel gene on chromosome 19p13 (7). EA2 is the most common of all 
episodic ataxias. The attacks are often associated with nausea, vomiting, dysarthria, 
or nystagmus, and last several hours to days. The frequency of these paroxysmal 
events varies from daily to once a year. The attacks are triggered by physical 
exertion, stress, or nonspecific febrile illness. In contrast with EA1, the attacks are 
not related to sudden movement. Approximately 50-70% of all patients with EA2 
are responsive to treatment with acetazolamide, concerning both the frequency and 
the severity of the attacks (8). Sodium valproate may be a necessary adjunct to 
acetazolamide (9).
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Case presentation
A 6-year-old girl was presented with a 3 year-long 
history of episodic instability, upward gaze, vomiting, 
vertigo, and cerebellar signs (dysmetria and dysarthric 
speech). She was developmentally normal. Her parents 
were not consanguine. Her family history showed no 
cases of similar illness. The first attack had begun at 21 
months of age with sudden onset of upward gaze and 
nausea after a febrile disease, which led to hospitalization 
with suspicious diagnosis of seizure and lasted for two 
days. Thereafter, her mother mentioned the recurrence 
of similar attacks after every febrile disease, which 
did not respond to usual symptomatic treatments. 
Downward gaze palsy existed as a common sign in all 
her attacks. The attacks occured approximately once a 
month and between them, she was completely normal. 
Her symptoms were relieved during sleep, and were not 
related to bath, foods and exercise. Blood cell counts, 
urinalysis, blood and urine amino acid chromatography, 
liver and renal function tests, blood gases, serum 
biochemistry and electrolytes all were in normal 
ranges. Auditory-evoked potentials, cerebrospinal fluid 
(CSF) studies, electroencephalogram (EEG), and brain 
magnetic resonance imaging (MRI) were also normal. 
The patient was hospitalized several times with various 
diagnoses, such as inherited metabolic disorder, basilar 
migraine, and epilepsy, and was treated with several 
drugs that were not effective. Then, suspicious diagnosis 
of EA2 was made and acetazolamide was prescribed. 
The frequency and severity of her symptoms decreased 
after receiving acetazolamide. Approximately 2 months 
after the last treatment (acetazolamide 250 mg twice 
a day orally), the patient’s attacks were completely 
resolved. At present she is a 7-year old excellent student 
and goes to school regularly. 
In conclusion, EA2 is an autosomal dominant disorder 
characterized by intermittent vertigo, ataxia, and 
interictal gaze-evoked nystagmus (10). The underlying 
cause of EA2 is a genetic alteration in the voltage-
dependent calcium channel (CACNA1A) (11). Episodes 
may occur spontaneously or may be triggered by stress 
and exertion (5,12). In our patient, episodic attacks 
was always occurring after a period of fever and was 
not related to bath, carbohydrate-rich foods, drinks, tea, 
caffeinated food, and exercise. Episodic ataxia most 
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acetazolamide, her attacks 
were controlled. Acetazolamide, a carbonic anhydrase 
inhibitor, is effective in reducing the frequency of ataxic 
episodes in some patients (8,13).
The drug’s mechanism of action is alteration of 
intracellular pH. The attacks are precipitated by high 
intracellular pH values, exercise, and stress through 
hyperventilation and consequent alkalosis (11). 
Acetazolamide decreases the intracellular pH, which 
reduces potassium conductance and thereby restores 
excitability and resting activity of the neurons (14). 
Nystagmus with features of rebound nystagmus is seen 
in between attacks (15), but interictally, our patient was 
completely normal. Although patients are asymptomatic 
between attacks, neurologic examination may reveal 
ocular abnormalities, including downbeating or gaze-
evoked nystagmus, abnormal optokinetic nystagmus, 
hypermetric saccades, saccadic pursuit, or myokymia 
(16,17). 
Our patient was hospitalized several times with incorrect 
diagnosis and she had no improvement. Considering that 
our diagnosis was made based on the manifestations 
of EA2, her attacks were completely controlled and 
resolved after treatment with acetazolamide. We did 
not perform mutation analysis, but the diagnosis of 
EA2 was confirmed based on the clinical manifestation 
and responsiveness to acetazolamide, but not to other 
drugs. Singhvi et al. also reported a case of EA2 that 
was confirmed according to clinical manifestation and 
responsiveness to acetazolamide (18). It is obvious that 
mutation analysis is very helpful, but it is not obligatory 
and patients can be diagnosed by experimental 
prescription and spending less money.
Downward vertical gaze palsy as a prominent ictal sign 
has not yet been reported in any literature. Presence 
of downward vertical gaze palsy in the attacks of our 
typically presents itself in the teenage years, but 
the time of onset can range from early childhood to 
early adulthood. However, EA2 does not shorten life span 
but significantly influences the quality of life. The clinical
 features and the family history are the basis for diagnosis. 
Molecular  diagnosis  is  available  on  a  research  basis.  MRI 
may  show  selective  atrophy  of  the  cerebellar  vermis  (7). 
Our  patient’s  family  history  and all  of  her  workup were 
negative,  so,  it  seems that  a  high index of  suspicion is 
necessary. After treatment with 
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13. Lubbers WJ, Brunt ER, Scheffer H, Litt M, Stulp R, Browne 
DL, et al. Hereditary myokymia and paroxysmal ataxia 
linked to chromosome 12 is responsive to acetazolamide. 
J Neurol Neurosurg Psychiatry 1995;59(4):400-5.
14. Shapiro MS, Gomeza J, Hamilton SE, Hille B, Loose 
MD, Nathanson NM, et al. Identification of subtypes of 
muscarinic receptors that regulate Ca2+ and K+ channel 
activity in sympathetic neurons. Life Sci 2001;68(22-
23):2481-7.
15. Baloh RW. Episodic vertigo: Central nervous system 
causes. Curropin Neurol 2002;15(1):17-21
16. VanDyke DH, Griggs RC, Murphy MJ, Goldstein MN. 
Hereditary myokymia and periodic ataxia. J Neurolog Sci 
1975;25(1):109-18.
17. Jen J, Kim GW, Baloh RW. Clinical spectrum of episodic 
ataxia type 2. Neurology 2004;62(1):17-22.
18. Singhvi JP, Prabhakar S, Singh P. Episodic ataxia: 
a case report and review of literature. Neurol India 
2000;48(1):78-80.
patient shows that in similar cases of episodic ataxias 
accompanied by ictal sign, diagnosis of EA2 should be 
considered.
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